-
1.发明公开公开(公告)号：US20240350603A1
公开(公告)日：2024-10-24
申请号：US18761799
申请日：2024-07-02
IPC分类号： A61K39/00 , G01N33/50 , G01N33/569
CPC分类号： A61K39/0011 , G01N33/505 , G01N33/5052 , G01N33/56977 , A61K2039/5158 , A61K2039/605 , A61K2039/6081
摘要： The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by:
a) obtaining neoepitope sequence data from the tumor of a subject;
b) obtaining immune competent cells;
c) using the neoepitope sequence data to generate a neoepitope presentation system;
d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and
e) quantifying the triggering of the immune response from the contacted immune competent cells.-
2.发明授权公开(公告)号：US12053512B2
公开(公告)日：2024-08-06
申请号：US16465675
申请日：2017-12-05
IPC分类号： G01N33/50 , A61K39/00 , G01N33/569
CPC分类号： A61K39/0011 , G01N33/505 , G01N33/5052 , G01N33/56977 , A61K2039/5158 , A61K2039/605 , A61K2039/6081
摘要： The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by: a) obtaining neoepitope sequence data from the tumor of a subject; b) obtaining immune competent cells; c) using the neoepitope sequence data to generate a neoepitope presentation system; d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and e) quantifying the triggering of the immune response from the contacted immune competent cells.
-
公开(公告)号：US20230377686A1
公开(公告)日：2023-11-23
申请号：US18359437
申请日：2023-07-26
发明人： Kevin B. Givechian , Kamil A. Wnuk , Chad Garner , Stephen Charles .Benz , Hermes J. Garban , Shahrooz Rabizadeh , Kayvan Niazi , Patrick Soon-Shiong
IPC分类号： G16B25/10 , C12Q1/6886
CPC分类号： G16B25/10 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
摘要： An immune gene expression signature is associated with favorable clinical features in Treg-enriched tumor samples and can be used to predict immunogenicity of a tumor, overall survival, and/or chemosensitivity.
-
公开(公告)号：US10525040B2
公开(公告)日：2020-01-07
申请号：US15738353
申请日：2016-06-29
发明人： Shahrooz Rabizadeh , Oleksandr Buzko , Paul Weingarten , Heather McFarlane , Connie Tsai , Stephen Charles Benz , Kayvan Niazi , Patrick Soon-Shiong
IPC分类号： A61K31/4196 , A61K45/06 , A61K31/538 , A61P35/00 , A61K31/4155 , A61K31/4178 , A61K31/4439
摘要： Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.
-
公开(公告)号：US11756651B2
公开(公告)日：2023-09-12
申请号：US16767366
申请日：2018-12-21
发明人： Kevin B. Givechian , Kamil A. Wnuk , Chad Garner , Stephen Charles Benz , Hermes J. Garban , Shahrooz Rabizadeh , Kayvan Niazi , Patrick Soon-Shiong
IPC分类号： G16B25/10 , C12Q1/6886
CPC分类号： G16B25/10 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
摘要： An immune gene expression signature is associated with favorable clinical features in Treg-enriched tumor samples and can be used to predict immunogenicity of a tumor, overall survival, and/or chemosensitivity.
-
公开(公告)号：US10736884B2
公开(公告)日：2020-08-11
申请号：US16441980
申请日：2019-06-14
发明人： Shahrooz Rabizadeh , Oleksandr Buzko , Paul Weingarten , Heather McFarlane , Connie Tsai , Stephen Charles Benz , Kayvan Niazi , Patrick Soon-Shiong
IPC分类号： A61K31/4196 , A61K31/538 , A61K45/06 , A61P35/00 , A61K31/4155 , A61K31/4178 , A61K31/4439
摘要： Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.
-
公开(公告)号：US20220403007A1
公开(公告)日：2022-12-22
申请号：US17843247
申请日：2022-06-17
IPC分类号： C07K16/00 , G16B5/00 , G16B20/00 , G16B30/00 , G16B35/00 , G16C20/60 , A61K35/17 , C07K16/30 , C07K16/32 , C12Q1/6886 , G16B20/30 , G16B20/20 , G16B35/20 , G16B20/50 , A61P35/00 , A61K38/17 , A61K39/00 , A61K39/395 , A61K45/00 , C07K14/735
摘要： Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope, and most preferably in combination with a cellular or non-cellular component for use as a diagnostic or therapeutic agent.
-
公开(公告)号：US20180141998A1
公开(公告)日：2018-05-24
申请号：US15568487
申请日：2016-04-25
IPC分类号： C07K16/00 , G06F19/18 , A61K39/00 , A61K35/17 , C07K16/30 , C07K16/32 , G06F19/22 , A61K45/00 , A61K38/17 , A61P35/00 , C40B50/02 , G06F19/12 , C07K14/735 , A61K39/395
CPC分类号： C07K16/005 , A61K35/17 , A61K38/1774 , A61K39/0011 , A61K39/39558 , A61K45/05 , A61K2039/505 , A61K2039/55 , A61K2039/585 , A61P35/00 , C07K14/70535 , C07K16/30 , C07K16/32 , C07K2317/32 , C07K2317/34 , C07K2317/622 , C07K2317/92 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G16B5/00 , G16B20/00 , G16B30/00 , G16B35/00 , G16C20/60
摘要： Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope, and most preferably in combination with a cellular or non-cellular component for use as a diagnostic or therapeutic agent.
-
公开(公告)号：US20180086752A1
公开(公告)日：2018-03-29
申请号：US15563813
申请日：2016-04-01
发明人： Shahrooz Rabizadeh , Kayvan Niazi , Sasha Buzko , Paul Weingarten , Heather McFarlane , Anna Juncker-Jensen , Justin Golovato , Patrick Soon-Shiong , Chunlin Tao , David Ho
IPC分类号： C07D417/14 , C07D417/12 , C07F9/6558 , C07D471/06 , C07D417/04
CPC分类号： C07D417/14 , A61K31/427 , A61P35/00 , C07D277/46 , C07D417/04 , C07D417/12 , C07D471/06 , C07F9/65583
摘要： Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
-
公开(公告)号：US11421016B2
公开(公告)日：2022-08-23
申请号：US15568487
申请日：2016-04-25
IPC分类号： C07K16/00 , G16B5/00 , G16B20/00 , G16B30/00 , G16B35/00 , G16C20/60 , A61K35/17 , C07K16/30 , C07K16/32 , C12Q1/6886 , G16B20/30 , G16B20/20 , G16B35/20 , G16B20/50 , A61P35/00 , A61K38/17 , A61K39/00 , A61K39/395 , A61K45/00 , C07K14/735
摘要： Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope, and most preferably in combination with a cellular or non-cellular component for use as a diagnostic or therapeutic agent.
-
-
-
-
-
-
-
-
-
搜索结果
127 条记录 (耗时 0.027 秒)
